COMMUNIQUÉS West-GlobeNewswire

Soda Health closes oversubscribed $50M Series B led by General Catalyst to scale its Smart Benefits Operating System

03/12/2024 - 15:00

The fundraise will enable Soda Health to broaden its offering of data products and services, and expand its support to new benefit categories BENTONVILLE, Ark., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Soda Health , a health [...]

Alira Health Unveils 2024 Report on Antibody-Drug Conjugates Market

03/12/2024 - 15:00

Analysis projects 21% annual growth, with global sales expected to reach $39 billion by 2030. FRAMINGHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Alira Health, a global advisory and clinical research firm dedicated to [...]

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

03/12/2024 - 14:30

SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI [...]

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

03/12/2024 - 14:30

GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]

Dentsply Sirona to Participate in the 7th Annual Evercore ISI HealthCONx Conference

03/12/2024 - 14:30

CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7 th Annual Evercore ISI HealthCONx [...]

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/12/2024 - 22:35

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics [...]

Revolution Medicines Announces Commencement of Public Offering of Common Stock

02/12/2024 - 22:31

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

02/12/2024 - 22:30

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]

MacroGenics to Participate in Upcoming Investor Conference

02/12/2024 - 22:30

ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody- [...]

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024

02/12/2024 - 22:30

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024

02/12/2024 - 22:30

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]

Treace Appoints Guy Guglielmino as Chief Commercial Officer

02/12/2024 - 22:15

PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]

Certara Showcases 2024 Research Wins With Over 100 Papers Published

02/12/2024 - 22:15

The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed [...]

Capricor Therapeutics to Present at Upcoming Investor Conferences

02/12/2024 - 22:15

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]

Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.

02/12/2024 - 22:06

Reimbursement approval supports expanded access to effective, safe thrombus removal for patients suffering from deep vein thrombosis (DVT) in Japan IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. ( [...]

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

02/12/2024 - 22:05

Upon closing, the transaction would secure global IP rights for NKGen. NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer (“NK”) cell therapy is already [...]

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

02/12/2024 - 22:05

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral [...]

Inari Medical Announces Joint Venture in Greater China

02/12/2024 - 22:05

IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]

OrthoPediatrics Corp. to Host Educational and Networking Events at 20th Annual International Pediatric Orthopaedic Symposium (IPOS)

02/12/2024 - 22:05

Continues IPOS Corporate Partnership as Emerald-Level Sponsor WARSAW, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on [...]